EGFR and lung adenocarcinoma: NSCLCs harboring-activated EGFR mutations are addicted to EGFR signaling, and treatment with small-molecule EGFR-tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib demonstrated dramatic responses to lung adenocarcinomas with EGFR mutations (7,8).